Security
Neuropace, Inc. Common Stock · NPCE
NPCENASDAQCommon stockCurrentCIK 1528287Updated Oct 6, 2026
NPCE price & chart
Loading TradingView…
NASDAQ:NPCE on TradingView ↗About the company
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by First Light Asset Management, LLC regarding NeuroPace Inc
4 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 107,255,000Source | 96,303,000Source | 96,991,000Source | 106,114,000Source | 94,389,000Source | 98,898,000Source | 110,205,000Source | 98,853,000Source | 105,565,000Source | 94,647,000Source | 107,651,000Source | 114,106,000Source |
| Property, Plant and Equipment, NetUSD | 1,108,000Source | 1,041,000Source | 1,243,000Source | 1,156,000Source | 998,000Source | 1,283,000Source | 1,160,000Source | 1,048,000Source | 1,125,000Source | 1,052,000Source | 1,003,000Source | 1,064,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 20,648,000Source | 15,418,000Source | 12,538,000Source | 22,857,000Source | 12,844,000Source | 14,779,000Source | 27,019,000Source | 12,998,000Source | 21,692,000Source | 13,430,000Source | 18,058,000Source | 6,605,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 14,938,000Source | 11,561,000Source | 14,930,000Source | 13,554,000Source | 11,242,000Source | 14,788,000Source | 15,435,000Source | 11,631,000Source | 14,681,000Source | 12,851,000Source | 12,314,000Source | 7,482,000Source |
| Inventory, NetUSD | 18,135,000Source | 12,084,000Source | 18,111,000Source | 16,346,000Source | 11,363,000Source | 16,694,000Source | 13,580,000Source | 11,416,000Source | 16,896,000Source | 13,381,000Source | 11,214,000Source | 9,712,000Source |
| Assets, CurrentUSD | 95,330,000Source | 82,591,000Source | 86,193,000Source | 93,742,000Source | 80,226,000Source | 86,978,000Source | 97,478,000Source | 84,254,000Source | 94,073,000Source | 81,339,000Source | 92,719,000Source | 97,714,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,243,000Source | 2,116,000Source | 1,453,000Source | 1,701,000Source | 2,084,000Source | 1,515,000Source | 2,201,000Source | 2,262,000Source | 1,438,000Source | 2,352,000Source | 2,737,000Source | 3,111,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,575,000Source | 12,246,000Source | 9,216,000Source | 11,007,000Source | 12,641,000Source | 9,679,000Source | 11,430,000Source | 13,027,000Source | 10,132,000Source | 11,843,000Source | 13,405,000Source | 14,838,000Source |
| Other Assets, NoncurrentUSD | 120,000Source | 15,000Source | 98,000Source | 87,000Source | 15,000Source | 106,000Source | 15,000Source | 15,000Source | 113,000Source | 15,000Source | 15,000Source | 21,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 88,737,000Source | 86,480,000Source | 85,108,000Source | 86,676,000Source | 84,504,000Source | 84,444,000Source | 85,936,000Source | 84,512,000Source | 86,534,000Source | 86,634,000Source | 86,997,000Source | 79,329,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 33,000Source | 30,000Source | 34,000Source | 33,000Source | 29,000Source | 34,000Source | 33,000Source | 29,000Source | 34,000Source | 30,000Source | 28,000Source | 25,000Source |
| Additional Paid in CapitalUSD | 568,171,000Source | 535,493,000Source | 577,153,000Source | 565,595,000Source | 530,104,000Source | 573,524,000Source | 561,775,000Source | 527,046,000Source | 571,412,000Source | 538,933,000Source | 524,435,000Source | 506,713,000Source |
| Retained Earnings (Accumulated Deficit)USD | -549,686,000Source | -525,700,000Source | -565,304,000Source | -546,190,000Source | -520,248,000Source | -559,104,000Source | -537,539,000Source | -512,734,000Source | -552,415,000Source | -530,950,000Source | -503,809,000Source | -470,853,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -1,108,000Source |
| Stockholders' Equity Attributable to ParentUSD | 18,518,000Source | 9,823,000Source | 11,883,000Source | 19,438,000Source | 9,885,000Source | 14,454,000Source | 24,269,000Source | 14,341,000Source | 19,031,000Source | 8,013,000Source | 20,654,000Source | 34,777,000Source |
| Liabilities and EquityUSD | 107,255,000Source | 96,303,000Source | 96,991,000Source | 106,114,000Source | 94,389,000Source | 98,898,000Source | 110,205,000Source | 98,853,000Source | 105,565,000Source | 94,647,000Source | 107,651,000Source | 114,106,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 19,607,000Source | 14,781,000Source | 17,433,000Source | 17,143,000Source | 12,585,000Source | 16,168,000Source | 14,707,000Source | 13,110,000Source | 17,814,000Source | 15,156,000Source | 16,229,000Source | 10,976,000Source |
| Operating Lease, Liability, CurrentUSD | 2,051,000Source | 1,800,000Source | 2,256,000Source | 1,986,000Source | 1,741,000Source | 2,186,000Source | 1,923,000Source | 1,683,000Source | 2,117,000Source | 1,860,000Source | 1,627,000Source | 1,415,000Source |
| Accounts Payable, CurrentUSD | 4,590,000Source | 2,160,000Source | 4,204,000Source | 4,721,000Source | 2,290,000Source | 4,512,000Source | 4,046,000Source | 3,268,000Source | 2,217,000Source | 2,954,000Source | 2,332,000Source | 2,147,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,382,000Source | 12,433,000Source | 8,661,000Source | 10,917,000Source | 12,903,000Source | 9,255,000Source | 11,441,000Source | 13,363,000Source | 9,836,000Source | 11,953,000Source | 13,814,000Source | 15,440,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 12,317,000Source | 10,072,000Source | 10,850,000Source | 9,740,000Source | 7,745,000Source | 9,344,000Source | 8,058,000Source | 7,290,000Source | 13,339,000Source | 9,787,000Source | 11,180,000Source | 7,414,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 60,000,000Source | 56,800,000Source | 51,700,000Source | 62,100,000Source | 55,500,000Source | 54,000,000Source | 66,300,000Source | 58,900,000Source | 61,100,000Source | 52,800,000Source | 66,500,000Source | 77,400,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 58,748,000Source | 59,266,000Source | 59,014,000Source | 58,616,000Source | 59,016,000Source | 59,021,000Source | 59,788,000Source | 58,039,000Source | 58,884,000Source | 59,525,000Source | 56,954,000Source | 52,913,000Source |
| Short-term InvestmentsUSD | 39,366,000Source | 41,412,000Source | 39,161,000Source | 39,284,000Source | 42,693,000Source | 39,202,000Source | 39,243,000Source | 45,947,000Source | 39,366,000Source | 39,325,000Source | 48,396,000Source | 70,804,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,278,000Source | 2,626,000Source | 11,089,000Source | 10,282,000Source | 9,558,000Source | 8,349,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 108,000Source | 2,585,000Source | 1,830,000Source | 537,000Source | 4,850,000Source | 391,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -125,000Source | 243,000Source | 3,673,000Source | 2,418,000Source | 1,698,000Source | 2,133,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,195,000Source | 966,000Source | -730,000Source | 671,000Source | 240,000Source | 647,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,900,000Source | -7,482,000Source | -11,006,000Source | -17,949,000Source | -19,701,000Source | -36,869,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -117,000Source | -37,000Source | -332,000Source | 8,994,000Source | 23,027,000Source | 23,797,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 117,000Source | 37,000Source | 332,000Source | 306,000Source | 173,000Source | 603,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 176,000Source | 228,000Source | 543,000Source | 881,000Source | 259,000Source | 59,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 0Source | 49,546,000Source | 49,546,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -166,000Source | 21,108,000Source | 19,600,000Source | 4,327,000Source | 8,127,000Source | 490,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -6,183,000Source | 13,589,000Source | 8,262,000Source | -4,628,000Source | 11,453,000Source | -12,582,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 20,770,000Source | 15,540,000Source | 12,779,000Source | 22,979,000Source | 15,631,000Source | 27,141,000Source | 21,814,000Source | 13,552,000Source | 18,180,000Source | 6,727,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,388,000Source | 1,890,000Source | 6,196,000Source | 6,226,000Source | 4,476,000Source | 4,464,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,628,000Source | 2,591,000Source | 2,303,000Source | 3,228,000Source | 2,278,000Source | 2,626,000Source | 11,089,000Source | 10,282,000Source | 9,558,000Source | 8,349,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 68,000Source | 49,000Source | 237,000Source | 228,000Source | 283,000Source | 258,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 60,000,000Source | 56,800,000Source | 51,700,000Source | 62,100,000Source | 54,000,000Source | 66,300,000Source | 61,100,000Source | 52,800,000Source | 66,500,000Source | 77,400,000Source |
| DepreciationUSD | — | — | 100,000Source | 100,000Source | 100,000Source | 100,000Source | 60,000Source | 49,000Source | 238,000Source | 207,000Source | 172,000Source | 267,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | -165,000Source | -82,000Source | 41,000Source | 229,000Source | -315,000Source | -356,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | -2,000Source | -14,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -527,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 4,594,000Source | 3,980,000Source | 5,027,000Source | 6,068,000Source | 4,844,000Source | 4,046,000Source | 19,090,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,645,000Source | 2,182,000Source | 1,539,000Source | 2,059,000Source | 1,521,000Source | 2,153,000Source | 7,457,000Source | 8,798,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 76,000Source | 44,000Source | 159,000Source | 251,000Source | 196,000Source | 243,000Source |
| Investment Income, InterestUSD | — | — | 667,000Source | 754,000Source | 523,000Source | 718,000Source | 565,000Source | 793,000Source | 2,816,000Source | 3,024,000Source | 3,050,000Source | 1,578,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,496,000Source | -5,452,000Source | -6,200,000Source | -8,651,000Source | -6,689,000Source | -6,589,000Source | -21,465,000Source | -27,141,000Source | -32,956,000Source | -47,082,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,496,000Source | -5,452,000Source | — | -8,651,000Source | -6,689,000Source | -6,589,000Source | -21,465,000Source | -27,141,000Source | -32,956,000Source | -47,082,000Source |
| Operating ExpensesUSD | — | — | 23,768,000Source | 19,663,000Source | 24,049,000Source | 24,402,000Source | 23,616,000Source | 22,489,000Source | 93,558,000Source | 80,756,000Source | 75,296,000Source | 73,287,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 82,000Source | 219,000Source | -41,000Source | -486,000Source | -165,000Source | -82,000Source | -486,000Source | 304,000Source | -315,000Source | -337,000Source |
| Debt Securities, Realized Gain (Loss) | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 27,354,000Source | 21,060,000Source | 22,826,000Source | 19,501,000Source | 22,068,000Source | 22,524,000Source | 99,986,000Source | 79,906,000Source | 65,421,000Source | 45,520,000Source |
| Cost of RevenueUSD | — | — | 6,186,000Source | 5,640,000Source | 3,920,000Source | 3,288,000Source | 4,020,000Source | 5,182,000Source | 22,766,000Source | 20,821,000Source | 17,299,000Source | 13,027,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 13,909,000Source | — | — | — | 15,049,000Source | — | 57,103,000Source | 54,518,000Source | 51,341,000Source |
| Operating Income (Loss)USD | — | — | -2,600,000Source | -4,243,000Source | -5,143,000Source | -8,189,000Source | -5,568,000Source | -5,147,000Source | -16,338,000Source | -21,671,000Source | -27,174,000Source | -40,794,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 82,000Source | 219,000Source | -41,000Source | -486,000Source | -165,000Source | -82,000Source | -486,000Source | 304,000Source | -315,000Source | -337,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,496,000Source | -5,452,000Source | -6,200,000Source | -8,651,000Source | -6,689,000Source | -6,589,000Source | -21,465,000Source | -27,141,000Source | -32,956,000Source | -47,082,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.11Source | -0.19Source | -0.18Source | -0.26Source | -0.2Source | -0.21Source | -0.66Source | -0.93Source | -1.27Source | -1.91Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.11Source | -0.19Source | -0.18Source | -0.26Source | -0.2Source | -0.21Source | -0.66Source | -0.93Source | -1.27Source | -1.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 33,134,606Source | 29,444,625Source | 34,104,430Source | 32,863,031Source | 33,716,813Source | 31,480,911Source | 32,722,438Source | 29,126,314Source | 25,851,813Source | 24,594,784Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 33,134,606Source | 29,444,625Source | 34,104,430Source | 32,863,031Source | 33,716,813Source | 31,480,911Source | 32,722,438Source | 29,126,314Source | 25,851,813Source | 24,594,784Source |
| Interest Expense (non-operating)USD | — | — | 1,645,000Source | 2,182,000Source | 1,539,000Source | 2,059,000Source | 1,521,000Source | 2,153,000Source | 7,457,000Source | 8,798,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,594,000Source | 3,980,000Source | 5,027,000Source | 6,068,000Source | 4,844,000Source | 4,046,000Source | 19,090,000Source | — | — | — |
| Gross ProfitUSD | — | — | 21,168,000Source | 15,420,000Source | 18,906,000Source | 16,213,000Source | 18,048,000Source | 17,342,000Source | 77,220,000Source | 59,085,000Source | 48,122,000Source | 32,493,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 8,517,000Source | 7,529,000Source |
| Investment Income, InterestUSD | — | — | 667,000Source | 754,000Source | 523,000Source | 718,000Source | 565,000Source | 793,000Source | 2,816,000Source | 3,024,000Source | 3,050,000Source | 1,578,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,496,000Source | -5,452,000Source | — | -8,651,000Source | -6,689,000Source | -6,589,000Source | -21,465,000Source | -27,141,000Source | -32,956,000Source | -47,082,000Source |
| Operating ExpensesUSD | — | — | 23,768,000Source | 19,663,000Source | 24,049,000Source | 24,402,000Source | 23,616,000Source | 22,489,000Source | 93,558,000Source | 80,756,000Source | 75,296,000Source | 73,287,000Source |
| Research and Development ExpenseUSD | — | — | 6,576,000Source | 5,754,000Source | 6,898,000Source | 6,845,000Source | 7,189,000Source | 7,440,000Source | 27,888,000Source | 23,653,000Source | 20,778,000Source | 21,946,000Source |
| Selling and Marketing ExpenseUSD | — | — | 12,598,000Source | 9,929,000Source | 12,124,000Source | 11,489,000Source | 11,583,000Source | 11,003,000Source | 46,580,000Source | — | — | — |
| Debt Securities, Realized Gain (Loss) | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
d138221dex991.htm · 8-K · 2026-07-28
EX-99.1 2 d138221dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy - Company received communication from FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form and that additional clinical evidence from the NAUTILUS trial and literature supporting the submission has been requested - - FDA has invited continued dialogue, and NeuroP…
Read attachment ↗d941443dex991.htm · 8-K · 2025-06-24
EX-99.1 2 d941443dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Announces Strategic CFO Transition Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role Mountain View, Calif. - June 24, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appo…
Read attachment ↗d830824dex991.htm · 8-K · 2025-06-04
EX-99.1 2 d830824dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Secures Up to $75 Million in Debt Financing Mountain View, Calif. - June 4, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company has entered into a new $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility. Proceeds from the new term loa…
Read attachment ↗d909963dex991.htm · 8-K · 2025-05-27
EX-99.1 2 d909963dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study - NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy - Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS ® System - Prima…
Read attachment ↗d902268dex991.htm · 8-K · 2025-04-14
EX-99.1 2 d902268dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Provides Update on Tariff Status - Minimal expected impact to operations and financial results - - Company to report first quarter 2025 financial results on May 13, 2025 - Mountain View, Calif. - April 14, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While sp…
Read attachment ↗d949067dex991.htm · 8-K · 2025-04-02
EX-99.1 2 d949067dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Announces Refocusing of Product Portfolio - Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 - - Maintaining 2025 Revenue Guidance - - No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR - Mountain View, Calif. - April 2, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of…
Read attachment ↗